Abu Dhabi - Sharikat Mubasher: M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, announced a strategic investment and partnership in longevity biotech leader Juvenescence to develop a pipeline of innovative medicines.
As part of this investment, both entities will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases, the company announced in a recent statement.
This partnership underlines M42's commitment to advancing its capabilities in drug discovery and development following the creation of its Integrated Health Solutions and Life Sciences platforms under its new operating structure announced recently.
M42 will integrate its deep expertise in genomics, biobanking, and clinical trial infrastructure with Juvenescence’s cutting-edge AI-enabled discovery technology and extensive drug development expertise to drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical trials.
Commenting on this milestone, Hasan Al Nowais, Managing Director and Group Chief Executive Officer at M42, stated that the partnership with Juvenescence will enable the company to take great strides in reinforcing Abu Dhabi’s push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges.
“With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide,” Al Nowais added.
For his part, Richard Marshall, Chief Executive Officer at Juvenescence, commented: “This powerful partnership will combine M42’s expertise in AI, technology, and genomics with Juvenescence’s unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.”
By partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine.
